Heartburn refractory to proton-pump inhibitors

被引：0
作者：
Trivedi A. [1 ]
Long J.D. [1 ]
机构：
[1] GI Neuromuscular Disorders Program, Section of Gastroenterology, Wake Forest University Baptist Medical Center, Winston-Salem, NC 27157, Medical Center Boulevard
来源：
Current Treatment Options in Gastroenterology | 2007年 / 10卷 / 1期
关键词：
Baclofen; Lansoprazole; Main Drug Interaction; Erosive Esophagitis; Eosinophilic Esophagitis;
D O I：
10.1007/s11938-007-0056-5
中图分类号：
学科分类号：
摘要：
The most appropriate diagnostic and therapeutic approach to patients with heartburn that persists despite the use of proton-pump inhibitor (PPI) therapy currently is not known. In general, patients with heartburn refractory to PPIs may have more than one explanation for their persistent symptoms. These include uncontrolled esophageal acid exposure ("PPI failure") in a small subset of patients, as well as other potential etiologies in the majority of patients who have controlled esophageal acid exposure on PPI therapy ("PPI success"). Some potential explanations for persistent heartburn in this latter group include hypersensitivity to acid reflux, nonacidic or duodenogastric esophageal reflux, as well as functional heartburn. Patients who present with heartburn refractory to PPIs should be investigated further to determine the potential cause. We believe the diagnostic modality with the most clinical usefulness is 24-hour pH and multichannel intraluminal impedance monitoring with symptom index performed while the patient is on high-dose PPI therapy. This approach allows the patient to be properly categorized and also identifies a substantial proportion of patients who will have functional heartburn, a condition that should discourage the use of endoscopic or surgical therapies. Therapeutic options for patients with heartburn refractory to PPIs are limited and have not been thoroughly studied. As a result of the paucity of information, we favor a therapeutic approach based on the outcome of diagnostic testing. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码：47 / 56
页数：9
相关论文
共 37 条
  • [1] Locke III G.R., Talley N.J., Fett S.L., Et al., Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmstead County, Minnesota, Gastroenterology, 112, pp. 1448-1456, (1997)
  • [2] Barlow W.J., Orlando R.C., The pathogenesis of heartburn in nonerosive reflux disease: A unifying hypothesis, Gastroenterology, 128, pp. 771-778, (2005)
  • [3] Fass R., Shapiro M., Dekel R., Sewell J., Systematic review: Proton-pump inhibitor failure in gastro-oesophageal reflux disease - Where next?, Aliment Pharmacol Ther, 22, pp. 79-94, (2005)
  • [4] Castell D.O., Kahrilas P.J., Richter J.E., Et al., Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis, Am J Gastroenterol, 97, pp. 575-583, (2002)
  • [5] Dean B.B., Gano A.D., Knight K., Et al., Effectiveness of proton pump inhibitors in nonerosive reflux disease, Clin Gastroenterol Hepatol, 2, pp. 656-664, (2004)
  • [6] Gallup Study of Consumers' Use of Stomach Relief Products, (2000)
  • [7] Egan L.J., Myhre G.M., Mays D.C., Et al., CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: Variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms, Aliment Pharmacol Ther, 17, pp. 1521-1528, (2003)
  • [8] Peghini P.L., Katz P.O., Bracy N.A., Castell D.O., Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors, Am J Gastroenterol, 93, pp. 763-767, (1998)
  • [9] Nzeako U.C., Murray J.A., An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy, Aliment Pharmacol Ther, 16, pp. 1309-1316, (2002)
  • [10] Galmiche J.P., Clouse R.E., Balint A., Et al., Functional esophageal disorders, Gastroenterology, 130, pp. 1459-1465, (2006)
1234